-
Goldman Sachs Tweaks PRX Estimates
Friday, February 25, 2011 - 10:36am | 101Goldman Sachs says that it is only modestly tweaking its Par Pharmaceutical (NYSE: PRX) estimates “following the quarter despite the miss, assuming that higher spending will not repeat going forward with operating expenses falling broadly in line with management's 3-year guidance.” “Continued slow...
-
UPDATE: Piper Jaffray Color On SLXP PT Decrease
Friday, February 25, 2011 - 9:01am | 148Piper Jaffray, which lowered its PT on shares of Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), is providing some color on the stock. “With yesterday's weakness in the wake of the FDA setback on Xifaxan in non-constipation irritable bowel syndrome (IBS), we believe SLXP shares are trading at an...
-
Piper Jaffray Lowers PT On Salix Pharmaceuticals To $39
Friday, February 25, 2011 - 8:39am | 27Piper Jaffray has lowered the price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $60 to $39 and maintains its Overweight rating.
-
Canaccord Downgrades DDSS To Hold
Friday, February 25, 2011 - 7:51am | 39Analysts at Canaccord downgrade Labopharm Inc (NASDAQ: DDSS) from “buy” to “hold.” DDSS shares dipped 10.38% to close at $0.733 yesterday. More Analyst Ratings here
-
Fast Money Pops & Drops, February 24th (OCR, PCLN, MU, SLXP, NEM)
Thursday, February 24, 2011 - 9:05pm | 251On CNBC's Fast Money, Karen Finerman said that Omnicare's (NYSE: OCR) conference call was pretty good, and she also said that she likes the new CEO. Omnicare, Inc. (OCR) gained 6.41% in the regular trading session, but it surrendered its gains in the after hours. Salix Pharmaceuticals, Ltd. (NASDAQ...
-
Leaving on a Jet Plane, Will the Market Come Back Again? 02-24-2011
Thursday, February 24, 2011 - 4:06pm | 958Cusick's Corner Looks like Colonel Gadhafi is singing a new tune, “I am leaving on a jet plane. I don't know when I'll be back again...” (I never thought I would ever incorporate a Peter, Paul & Mary song.) There are reports that Gadhafi is attempting to flee the country. While the initial...
-
Calls Purchased on Forest Laboratories (FRX)
Thursday, February 24, 2011 - 3:17pm | 148Shares of Forest Laboratories (NYSE: FRX) are lower on the session by 0.03%, currently trading at $31.99. The stock had been moving largely higher over the past two months, but recently sold off and is now trading between the 50-day and 200-day moving averages. Options traders are buying calls on...
-
Shire Receives New Paragraph IV Notice Letter From Watson for ADDERALL XR
Thursday, February 24, 2011 - 12:17pm | 120Shire plc (NASDAQ: SHPGY) announces that its subsidiaries Shire LLC and Shire Development Inc. have received a new Paragraph IV Notice Letter from Watson Laboratories, Inc. in Fort Lauderdale, Florida advising of the filing of an Abbreviated New Drug Application for a generic version of all...
-
Benzinga's Top Pre-Market NASDAQ Losers (SLXP, AXTI, IDCC, CLMT)
Thursday, February 24, 2011 - 9:33am | 132Salix Pharmaceuticals Ltd (NASDAQ: SLXP) dipped 24.25% to $31.40 in the pre-market session. SLXP expects the US Food and Drug Administration to seek more data for its Xifaxan drug. AXT Inc (NASDAQ: AXTI) fell 9.45% to $7.57 in the pre-market session. AXTI reported weaker-than-expected Q4 results...
-
Mylan Reports Q4 EPS od $0.45 vs. $0.45; Revenues $1.43B vs. $1.46B
Thursday, February 24, 2011 - 8:48am | 63Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three ended December 31, 2010. Adjusted diluted EPS of $0.45 for the quarter ended December 31, 2010 compared to $0.33 for the same prior year quarter, an increase of 36%; Total revenues of $1.43 billion for the quarter ended...
-
Par Pharmaceutical Reports Q4 EPS of $0.61 vs. $0.67
Thursday, February 24, 2011 - 8:46am | 150Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the fourth quarter and full year ended December 31, 2010. For the fourth quarter ended December 31, 2010, the Company reported total revenues of $227 million and income from continuing operations of $17.6 million, or $0.48...
-
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash (WCRX, VRTX, ENDP, UTHR)
Thursday, February 24, 2011 - 3:44am | 139Below are the top mid-cap drug manufacturers-other stocks on the NYSE and the NASDAQ in terms of cash. Warner Chilcott plc (NASDAQ: WCRX) had $1.07 billion in total cash and $5.22 billion in total debt for the latest quarter. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had $1.03 billion in...
-
Questcor Reports 2010 Financial Results
Wednesday, February 23, 2011 - 5:08pm | 176Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the full year and fourth quarter ended December 31, 2010. For the year ended December 31, 2010, net sales increased 30.4 percent to a record $115.1 million from $88.3 million in the prior year. The Company's...
-
Court of Appeals Overturns $1.8B Patent Verdict for Johnson & Johnson Subsidiary
Wednesday, February 23, 2011 - 2:23pm | 158Centocor Ortho Biotech Inc. today received a decision from the Court of Appeals for the Federal Circuit in Washington, D.C. overturning a 2009 federal court jury verdict that awarded the company $1.8 billion after finding Abbott Laboratories (NYSE: ABT) liable for patent infringement. A panel of...
-
Calls Purchased on Forest Laboratories (FRX)
Wednesday, February 23, 2011 - 11:44am | 139Shares of Forest Laboratories (NYSE: FRX) are lower on the session by 2.98%, currently trading at $31.92. The stock had been moving largely higher over the past six months, but recently came under selling pressure. It is currently trading between the 50-day and 200-day moving average. Options...